New Clinical Study Evaluates First Drug to Show Improvement in Subtype of Autism

Researchers at the Seaver Autism Center, led by Dr. Alex Kolevzon, have begun a clinical trial to evaluate insulin-like growth factor in children who have SHANK3 deficiency, a known cause of autism spectrum disorder. Click here to read the press release!

To view all posts, please click here.

This entry was posted in News. Bookmark the permalink.